Hydrochloorthiazide Mylan (Hydrochlorothiazide)

Hydrochloorthiazide Mylan is prescribed for several clinical situations in which reduction of excess extracellular fluid or control of elevated arterial pressure is needed. It may be used alone or in combination with other antihypertensive agents, depending on the therapeutic goal.

• Hypertension: helps lower systolic and diastolic blood pressure by decreasing plasma volume.
• Edema associated with congestive heart failure: reduces fluid accumulation in lungs and peripheral tissues.
• Edema due to renal disease such as nephrotic syndrome: promotes sodium and water excretion to alleviate swelling.
• Edema secondary to hepatic cirrhosis: assists in managing ascites and peripheral edema.
• Adjunct therapy for resistant hypertension: may be combined with other classes to achieve target blood pressure.

• Hydrochloorthiazide Mylan works by inhibiting the sodium‑chloride symporter located in the distal convoluted tubule of the nephron. This blockade reduces reabsorption of Na⁺ and Cl⁻, leading to increased urinary excretion of sodium, chloride, and water (natriuresis and diuresis). The resulting decrease in extracellular fluid volume lowers cardiac output and peripheral vascular resistance, contributing to blood pressure reduction. The effect begins within a few hours after oral administration and persists for up to 24 hours.

Like other thiazide diuretics, Hydrochloorthiazide Mylan may cause a range of adverse reactions, most of which are mild and reversible, while a few can be serious and require medical attention.

Common

• Increased urinary frequency and volume, leading to more trips to the bathroom.
• Mild electrolyte disturbances such as low potassium (hypokalemia) or low sodium (hyponatremia).
• Dizziness or light‑headedness, particularly on standing (orthostatic symptoms).
• Headache of mild to moderate intensity.
• General fatigue or weakness during the initial treatment period.

Serious

• Severe electrolyte imbalance, including marked hyponatremia, hypokalemia, or hyperuricemia.
• Acute gout attacks triggered by elevated uric acid levels.
• Significant dehydration or low blood pressure (hypotension) that may cause fainting.
• Allergic reactions such as rash, itching, swelling, or angioedema.
• Rare cases of pancreatitis presenting with abdominal pain and nausea.

When prescribing Hydrochloorthiazide Mylan, clinicians consider several precautionary factors to ensure safe use and to minimize risk of complications.

• Assess renal function before initiation and monitor periodically, as impaired kidneys can reduce drug clearance.
• Evaluate electrolyte levels, especially potassium and sodium, and correct abnormalities prior to treatment.
• Use caution in patients with a history of gout, as the medication may increase uric acid concentrations.
• Monitor blood pressure closely during the first weeks to avoid excessive hypotension.
• Consider pregnancy status; the safety profile in pregnancy is not well established.
• Avoid abrupt discontinuation, which may lead to fluid retention and rebound hypertension.

Hydrochloorthiazide Mylan can affect the pharmacokinetics or pharmacodynamics of other medicines; certain combinations should be avoided while others require careful monitoring.

Avoid

• Concurrent use with other potent diuretics, which may cause excessive fluid loss and electrolyte disturbances.
• Lithium therapy, as thiazides can increase lithium levels and risk toxicity.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs), which may reduce the diuretic’s antihypertensive effect.
• High‑dose corticosteroids, which can counteract the diuretic’s sodium‑excreting action.

Use with caution

• Antihypertensive agents such as ACE inhibitors, ARBs, or beta‑blockers, requiring blood pressure monitoring.
• Antidiabetic drugs, because changes in potassium may affect glucose control.
• Digoxin, as low potassium levels can increase the risk of digoxin toxicity.